Glycemic Variability in Diabetic Patients Adding Canagliflozin 300Mg to their Underlying Treatment

Background: The kidney is vital for the regulation of glucose. Sodium-glucose co-transporter-2 (SGLT2) receptors are located in the initial portion of the proximal tubule and are responsible for 80–90% of total glucose reabsorption. SGLT2 inhibitors are a new class of drugs tested to treat type 2 diabetes mellitus (DM) patients; their objective is to control glucose in an insulin-independent manner, viaglycosuria. Objective: This study aimed to determine the effects of oral canagliflozin on plasma glucose levels, in patients with T2D that is inadequately controlled by standard therapy. The drug was administered at a dose of 300 mg every 24 hours, and plasma glucose levels were being measured using the iPRO2 system.. Materials and methods: This is a pilot, prospective, and longitudinal study. Patients with uncontrolled diabetes determined by blood glucose and glycosylated hemoglobin levels> 7% were recruited, with no modification of treatment dosage (oral hypoglycemic agents or insulin treatment) in the previous 3 months. Blood pressure and somatometric measurements were obtained and recorded.300mg of canagliflozin was then added to their antidiabetic regimen. Patients were monitored using the iPRO2 system, and metabolic control was determined3 months after initiation of treatment. Results: A total of 26 patients were included in the study. Results shown normal distribution, analyzed by ANOVA, with and statistical significance at: HbA1c (p < 0.001), BMI (p < 0.001), and blood pressure (p < 0.05). Conclusion: Glycemic control is improved in diabetic patients when treated with Canagliflozin 300 mginsulinindependent correction of glycemic levels, demonstrated by iPRO2 monitoring.